View Cart  

Third-Party Manufacturing Concerns Draw CRL for Navidea’s Lymphoseek

A A
The FDA has sent Navidea a complete response letter (CRL) on its Lymphoseek injection, citing concerns over quality control at third-party contract manufacturing facilities.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00